In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, June 2013

Executive Summary

This Month's Profile Group: Medtech Start-Ups Aim To Reverse The Downward Spiral of Heart Failure, features profiles of BioVentrix, Calon Cardio-Technology, Cibiem, DC Devices, and LoneStar Heart. Plus these Start-Ups Across Health Care: Dialog Devices, Lumena Pharmaceuticals, and STAT-Diagnostica.

You may also be interested in...



STAT-Diagnostica & Innovation SL

Rapid diagnosis of infectious diseases can make the difference between life and death in hospitals, but the wait for results from standard hospital in-house laboratory tests may take days. STAT-Diagnostica & Innovation SL’s self-contained mini-lab is not only portable and can be administered easily by a nurse, but it also allows for a short, 30-minute turnaround time from taking a patient specimen to identifying one of roughly 50 specific pathogens associated mainly with infectious diseases.

Dialog Devices Ltd.

The Vascular Early Warning System from UK-based Dialog Devices Ltd. is a portable, handheld device to scan patients for peripheral arterial disease quickly in a primary care physician’s office. The automated functional test can be performed in about 10 minutes and improves upon the ankle brachial pressure index, which is the current first-line examination for suspected PAD.

LoneStar Heart Inc.

LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV004064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel